Trio links up for combination study
Immunicum AB is collaborating with Germany’s Merck KGaA and U.S.-based Pfizer for the evaluation of ilixadencel in combination with avelumab in a multi-indication Phase 1b/2 clinical trial. Ilixadencel is Immunicum's lead product, an off-the-shelf cell-based cancer immune primer. Immunicum planned to launch a study of the compound in the fourth quarter of 2018, and once the Phase 1b portion is complete, the Phase 2 portion will evaluate the safety and efficacy of combining avelumab and ilixadencel in patients with advanced head and neck cancer and gastric adenocarcinoma. Under this agreement, Immunicum will assume responsibility for the study, and maintains all rights to ilixadencel.
“We look forward to working with Immunicum to assess ilixadencel with avelumab. As part of our clinical development program for avelumab, this collaboration can help advance our understanding of the potential of immunotherapy combination regimens,” said Dr. Chris Boshoff, senior vice president and head of immuno-oncology, early development and translational oncology for Pfizer Global Product Development.